HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year

SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against Diverse Emerging Infectious Threats), a national consortium led by Albert Einstein College of Medicine and funded by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network.

HDT Bio will focus on developing “road maps” for the rapid creation of RNA vaccines against pathogens with pandemic potential, harnessing the company’s proprietary AMPLIFY™ self-amplifying replicon RNA (repRNA) platform and LION™ nanoparticle delivery system. The combination of these two technologies offers increased vaccine potency, durability, and stability, while simplifying production—critical features for addressing emerging infectious threats quickly and effectively.

“We are excited to contribute our expertise in RNA vaccine technologies to the PROVIDENT consortium,” said Steve Reed, Ph.D., Chief Executive Officer of HDT Bio. “Our AMPLIFY™ and LION™ platforms have demonstrated their ability to rapidly generate potent, durable immune responses with a favorable safety profile. These innovations will be essential in preparing for future pandemics, where speed and flexibility in vaccine development will save lives.”

As part of the PROVIDENT initiative, HDT Bio will develop a comprehensive strategy to create RNA vaccines capable of targeting pathogens across multiple viral families, focusing particularly on rapid adaptability to emerging “virus X” scenarios. This aligns with PROVIDENT’s broader goals of safeguarding public health by advancing platforms that can be quickly tailored to respond to novel viral threats.

“It is currently unknown if the state-of-the-art approaches used to design vaccine antigens for traditional vaccine technologies can simply be co-opted for use in RNA vaccine technologies,” said Jesse Erasmus, Ph.D., who is the principal investigator on the subaward. “In our project, Rapid-Response Roadmap for RNA vaccines, HDT Bio will address this unknown while generating prototype vaccine candidates for 8 different viruses across 3 virus families of pandemic potential, collaborating with other member institutions of PROVIDENT to design and characterize antigens using structure-guided and high-throughput mutagenesis approaches.”

“We will also evaluate safety and immunogenicity against a diverse panel of viruses, and characterize efficacy in high-containment,” Dr. Erasmus added.

The additional key contributors to these efforts at HDT Bio are:

Amit Khandhar, Ph.D., Director of FormulationsTaishi Kimura, Ph.D., Senior ScientistE. Taylor Stone, Ph.D., Scientist

HDT Bio will work with 12 teams in academia and government alongside 3 other projects titled, 1) “Discovery and dissection of virus-host interactions and pathogenetic mechanisms”, 2) “Antigen design and immunological evaluation”, and 3) Mining human antibody responses to inform vaccine and therapeutic design”. More details on collaborating institutions and their key researchers can be found in Albert Einstein College of Medicine’s description of the parent award.

HDT Bio’s LION™/repRNA platform builds on the company’s pioneering work in vaccine development, notably including emergency use authorizations for its vaccine during the COVID-19 pandemic. The company’s innovative approach to RNA vaccine delivery, particularly through its LION™ nanotechnology, enhances the safety and efficacy of RNA-based vaccines while maintaining crucial logistical benefits such as refrigeration stability and simplified manufacturing.

“Our role in PROVIDENT exemplifies HDT Bio’s mission to make RNA vaccines a cornerstone of future pandemic preparedness,” added Dr. Reed. “By working in concert with academic, government, and industry partners, we aim to provide the tools needed to address unknown viral threats quickly and efficiently.”

For more information on HDT Bio’s AMPLIFY™ and LION™ platforms, visit www.hdt.bio.

About HDT Bio

HDT Bio is a Seattle-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio’s work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company’s vaccine platforms combine formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses. HDT Bio’s repRNA/LION™ was the first self-amplifying RNA vaccine platform to ever receive a regulatory authorization.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hdt-bio-to-help-spearhead-rna-vaccine-development-in-national-pandemic-preparedness-initiative-302250815.html

SOURCE HDT Bio Corp.

The partnership integrates Whip Around’s fleet maintenance software with Linxup’s GPS tracking solutions for seamless data exchange.

ST. LOUIS, Sept. 17, 2024 /PRNewswire-PRWeb/ — Linxup, a leading provider of fleet management solutions, and Whip Around, a pioneering digital inspection and maintenance platform, are proud to announce the launch of their new API integration. This innovative partnership enables seamless data exchange between the two platforms, empowering fleet managers to streamline their operations, reduce costs, and improve overall efficiency.

The Linxup-Whip Around API integration allows for the automatic transfer of critical data points such as mileage, engine hours, DTCs, etc., for better maintenance planning and easier work order creation. This eliminates the need for manual data entry, reducing errors and increasing the speed of data processing. Fleet managers can now easily track and analyze vehicle maintenance and inspection data in real-time, enabling them to make data-driven decisions and optimize their fleet operations.

“We are thrilled to partner with Whip Around and bring this game-changing integration to the market,” said Drew Reynolds, CEO of Linxup. “Our shared commitment to innovation and customer satisfaction makes this partnership a natural fit. By integrating our platforms, we are empowering fleet managers to take their operations to the next level.”

Whip Around’s digital inspection and maintenance platform is designed to simplify the process of tracking and managing vehicle maintenance, reducing downtime, and improving overall fleet reliability. Linxup’s fleet management platform provides a comprehensive suite of tools for tracking and managing fleet operations, including vehicle tracking, maintenance scheduling, and reporting.

“This integration with Linxup represents a significant step forward in our mission to help businesses improve vehicle and asset uptime while streamlining operational efficiency,” said Noah Hickey, CEO of Whip Around. “By combining our strengths in inspections and maintenance with Linxup’s expertise in GPS tracking, we’re providing a solution that addresses the full spectrum of asset management and tracking needs.”

Key benefits of the Linxup-Whip Around API integration include:

Automated data transfer: Eliminate manual data entry and reduce errors.Real-time insights: Use critical data points to know when it’s time to create work orders and perform preventative maintenance.Improved decision-making: Make data-driven decisions to optimize fleet operations.Enhanced customer experience: Streamline operations and reduce downtime.

To learn more about the Linxup-Whip Around API integration and how it can benefit your fleet operations, please visit go.linxup.com/whip-around.

About Linxup

Linxup is a top provider of advanced GPS tracking, telematics, and fleet management solutions, dedicated to helping businesses of all sizes optimize their operations, enhance safety, and reduce costs. Our robust platform provides complete visibility into vehicles, assets, and tools, enabling businesses to drive efficiency and make informed decisions. Serving industries such as construction, landscaping, restoration, home services, and other field-based sectors, Linxup equips companies with the insights and tools to boost productivity and achieve operational excellence. Learn more at www.linxup.com.

About Whip Around

Established in 2016, Whip Around has quickly become North America’s easiest-to-use inspection and maintenance platform. Whip Around’s software and app help fleet managers, operators and mechanics improve safety and compliance and minimize costs through better inspection and maintenance processes for vehicles, equipment and assets. Learn more at www.whiparound.com.

Media Contact

Genifer Redington, Linxup, 1 314-532-5604, gredington@linxup.com, Linxup

View original content to download multimedia:https://www.prweb.com/releases/linxup-and-whip-around-announce-groundbreaking-api-integration-revolutionizing-fleet-management-302250709.html

SOURCE Linxup

NEW YORK, Sept. 17, 2024 /PRNewswire/ –The Board of Directors of Sivers Semiconductors AB (publ) (“Sivers Semiconductors” or the “Company”) (Nasdaq Stockholm: SIVE) has resolved, subject to approval by the Extraordinary General Meeting on 11 October 2024, to carry out a directed new share issue of 1,524,584 ordinary shares corresponding to approximately 6.9 million SEK to the Company’s CEO Vickram Vathulya (the “Directed Issue”). The Board of Directors has also proposed that the Extraordinary General Meeting resolve on an incentive program comprising a maximum of 7,500,000 employee stock options. Notice of the Extraordinary General Meeting will be published through a separate press release.

The Directed Issue

Vickram Vathulya, who took office as CEO of Sivers on 19 August 2024, has expressed interest in increasing his commitment to the Company through a larger investment where the invested amount is added to the Company. The Board has assessed that the Directed Issue to Vickram Vathulya increases his motivation and commitment to the Company, while the issue proceeds will strengthen the Company’s working capital.

The Board has therefore resolved, subject to approval by an extraordinary general meeting on 11 October 2024, to carry out the Directed Issue comprising 1,524,584 ordinary shares, corresponding to approximately 6.9 million SEK. Deviating from shareholders’ preferential rights, the new ordinary shares may only be subscribed for by Vickram Vathulya. The subscription price in the Directed Issue is 4.536 SEK per ordinary share. The subscription price has been determined through agreement between the Board of Directors and Vickram Vathulya and corresponds to the closing price of the ordinary share on Nasdaq Stockholm on 17 September 2024. The Board of Directors’ assessment is that the subscription price in the Directed Issue is carried out on market terms.

Through the Directed Issue, the number of shares in the Company will increase by a maximum of 1,524,584 shares, from 235,884,460 shares to 237,409,044 shares, and the share capital will increase by a maximum of 762,292 SEK, from 117,942,230 SEK to 118,704,522 SEK. The total dilution effect through the Directed Issue amounts to approximately 0.6 percent.

Incentive Program

In addition to the Directed Issue, the Board has proposed, as previously communicated, that the Extraordinary General Meeting resolves on an incentive stock option program intended for the Group’s employees (“P09”). The Board of Directors proposes that P09 shall consist of a maximum of 7,500,000 new stock options (the “Stock Options”) entitling to purchase of the same number of shares in the Company, corresponding to approximately 3.8 per cent of the share capital and votes in the Company after dilution. In total, the proposed P09 and the previous outstanding incentive programs corresponds to a dilution of not more than approximately 6.3 per cent of the share capital and votes of the Company after dilution.

The final number of Stock Options that the participants in Europe are eligible to exercise depends on the degree of fulfilment in respect of the performance conditions for the Group. Stock Options granted to participants in the US shall not be subject to performance conditions. The performance condition for P09 is based on the average growth of the Group’s net sales for the financial years 2024, 2025 and 2026 with 2023 actual as the calculation base.

The Stock Options shall be granted to the participants free of charge and may not be transferred or pledged. The Stock Options are vested after three years from the date of grant of the Stock Options, i.e. the participant must remain employed within the Group for three years in order for all Stock Options to vest.

The CEO is proposed to be allocated 2,000,000 Employee Stock Options within P09. However, Stock Options granted to the CEO will be conditional upon purchase or subscription of at least 2 million ordinary shares in the Company, however limited to USD 1 million. As of 13 September 2024, the CEO has purchased 475,416 ordinary shares on Nasdaq Stockholm and these shares will be included in the minimum investment for the CEO as referred to above.

Each Stock Option entitles the employee to acquire one share of Sivers Semiconductors during the period commencing on the third anniversary of date of grant and ending on the fifth anniversary of the date of grant at a price corresponding to 130 percent of the average volume-weighted share price for the Company’s share on Nasdaq Stockholm for the date of granting the Stock Options to the participant.

To implement the P09 in a cost-effective and flexible manner, the Board of Directors proposes that the obligations of the Company to deliver shares under the Stock Options are secured by an authorisation for the Board of Directors to resolve upon issue, repurchase and transfer of shares of series C which thereafter can be converted into ordinary shares.

For more information, please refer to the notice of the Extraordinary General Meeting which will be published through a separate press release.

Advisers

Setterwalls Advokatbyrå AB acts as legal adviser to the Company.

For more information, please contact:

Dr. Bami Bastani, Chairman of the Board of Directors
Tel: +1 908 87 28 370
E-mail: bami.bastani@sivers-semiconductors.com

Sivers Semiconductors AB (SIVE.ST) is a leader in SATCOM, 5G, 6G, Photonics, and Silicon Photonics that drives innovation in global communications and sensor technology. Our business units, Photonics and Wireless, supply cutting-edge, integrated chips and modules critical for high-performance gigabit wireless and optical networks. Catering to a broad spectrum of industries from telecommunication to aerospace, we fulfill the increasing demand for computational speed and AI application performance, replacing electric with optical connections for a more sustainable world. Our wireless solutions are forging paths in advanced SATCOM/5G/6G systems, while our photonics expertise is revolutionizing custom semiconductor photonic devices for optical networks and optical sensing, making us a trusted partner to Fortune 100 companies as well as emerging unicorns. With innovation at our core, Sivers Semiconductors is committed to delivering bespoke, high-performance solutions for a better-connected and safer world. Discover our passion for perfection at www.sivers-semiconductors.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sivers-semiconductors/r/the-board-of-directors-in-sivers-semiconductors-resolves-on-a-directed-share-issue-to-the-ceo-and-pr,c4038258

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/the-board-of-directors-in-sivers-semiconductors-resolves-on-a-directed-share-issue-to-the-ceo-and-proposes-an-incentive-program-for-the-groups-employees-302250820.html

SOURCE Sivers Semiconductors